AMRX
Amneal Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$20.86
−3.04%Price chart
Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2
Key dataNov 2, 2026
Open$21.53
From 52W high−3.04%
Volume864887.00
Market cap$6.66B
P/E (TTM)41.9x
P/S (TTM)2.1x
Div yield—
Key dataNov 2, 2026
Open
$21.53
From 52W high
−3.04%
Volume
864887.00
Market cap
$6.66B
ValuationView details →
P/E (Fwd)
19.2x
EV/EBITDA
14.4x
P/E (TTM)
41.9x
RSI (14)
66.1
MomentumView details →
1D Return
−3.04%
YTD Return
+69.29%
SummaryUpdated Jun 1, 2026
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is a specialty and generic pharmaceutical company founded in 2002 and headquartered in Bridgewater, New Jersey. The company went public in May 2018 following its transformation from Atlas Holdings, Inc. Amneal has evolved from a traditional generic drug manufacturer into a diversified pharmaceutical company with operations spanning generic medicines, specialty branded products, and healthcare distribution services. The company operates manufacturing facilities in the United States, India, and Ireland, serving customers globally through a comprehensive portfolio of pharmaceutical products and services.
Similar companies
Latest newsMore news →
Amneal Pharmaceuticals announced that it will report its third-quarter 2026 financial results before market open on November 3, 2026, and host an audio webcast at 8:30 a.m. ET.25d agoThe FDA approved Amneal Pharmaceuticals' Lanreotide Injection, a long-acting oncology treatment, and Amneal immediately launched the product commercially.45d ago